Background Circulating tumor DNA (ctDNA) carries information on tumor burden. However, the mutation spectrum is different among tumors. This study was designed to examine the utility of ctDNA for monitoring tumor burden based on an individual mutation profile. Methodology DNA was extracted from a total of 176 samples, including pre- and post-operational plasma, primary tumors, and peripheral blood mononuclear cells (PBMC), from 44 individuals with colorectal tumor who underwent curative resection of colorectal tumors, as well as nine healthy individuals. Using a panel of 50 cancer-associated genes, tumor-unique mutations were identified by comparing the single nucleotide variants (SNVs) from tumors and PBMCs with an Ion PGM sequencer. A gro...
Cancer is a disease of complex genetic alterations, and comprehensive genetic diagnosis is beneficia...
International audienceCancer is characterized by multiple somatic genetic and epigenetic alterations...
Background: The observation of tumor-derived cell-free DNA (ctDNA) in plasma brought new expectation...
<div><p>Background</p><p>Circulating tumor DNA (ctDNA) carries information on tumor burden. However,...
Background: Liquid biopsy has been proposed to be a promising noninvasive tool to obtain information...
Liquid biopsy has been proposed to be a promising noninvasive tool to obtain information on tumor pr...
International audienceBACKGROUND:Circulating tumor DNA (ctDNA) has emerged as a good candidate for t...
Introduction: The pressing need to determine the KRAS/BRAF mutational status for selecting patients ...
Molecular profiling of circulating tumor DNA (ctDNA) is a promising noninvasive tool. Here, next-gen...
International audienceBACKGROUND:Targeted therapies, although contributing to survival improvement i...
Early biomarkers of therapeutic responses can help optimize the treatment of metastatic colorectal c...
Cancer individualized therapy often requires for gene mutation analysis of tumor tissue. However, tu...
Mutation analysis of circulating tumor DNA (ctDNA) has recently been introduced as a noninvasive tum...
This project aimed to investigate the utility of RNF43 mutations for circulating tumour DNA (ctDNA) ...
BACKGROUND: Analysis of circulating free DNA (cfDNA) is a promising tool for personalized management...
Cancer is a disease of complex genetic alterations, and comprehensive genetic diagnosis is beneficia...
International audienceCancer is characterized by multiple somatic genetic and epigenetic alterations...
Background: The observation of tumor-derived cell-free DNA (ctDNA) in plasma brought new expectation...
<div><p>Background</p><p>Circulating tumor DNA (ctDNA) carries information on tumor burden. However,...
Background: Liquid biopsy has been proposed to be a promising noninvasive tool to obtain information...
Liquid biopsy has been proposed to be a promising noninvasive tool to obtain information on tumor pr...
International audienceBACKGROUND:Circulating tumor DNA (ctDNA) has emerged as a good candidate for t...
Introduction: The pressing need to determine the KRAS/BRAF mutational status for selecting patients ...
Molecular profiling of circulating tumor DNA (ctDNA) is a promising noninvasive tool. Here, next-gen...
International audienceBACKGROUND:Targeted therapies, although contributing to survival improvement i...
Early biomarkers of therapeutic responses can help optimize the treatment of metastatic colorectal c...
Cancer individualized therapy often requires for gene mutation analysis of tumor tissue. However, tu...
Mutation analysis of circulating tumor DNA (ctDNA) has recently been introduced as a noninvasive tum...
This project aimed to investigate the utility of RNF43 mutations for circulating tumour DNA (ctDNA) ...
BACKGROUND: Analysis of circulating free DNA (cfDNA) is a promising tool for personalized management...
Cancer is a disease of complex genetic alterations, and comprehensive genetic diagnosis is beneficia...
International audienceCancer is characterized by multiple somatic genetic and epigenetic alterations...
Background: The observation of tumor-derived cell-free DNA (ctDNA) in plasma brought new expectation...